Evaluating Pharmacists' Pharmacological Knowledge and Views Regarding Pfizer-BioNTech COVID-19 Vaccine in Saudi Arabia [0.03%]
评估沙特阿拉伯药剂师对辉瑞生物技术公司COVID-19疫苗的药理学知识和观点
Nasser Alorfi,Ahmed Ashour
Nasser Alorfi
Background: The Pfizer-BioNTech COVID-19 vaccine has been widely used and approved for the prevention of 2019 coronavirus disease (COVID-19) for individuals aged 16 years and older in Saudi Arabia. The emergency use autho...
Antileishmanial Activity of Tamoxifen by Targeting Sphingolipid Metabolism: A Review [0.03%]
他莫昔芬通过靶向鞘脂代谢发挥抗利什曼病活性：综述
Kaleab Alemayehu Zewdie,Haftom Gebregergs Hailu,Muluken Altaye Ayza et al.
Kaleab Alemayehu Zewdie et al.
Leishmaniasis is a widespread group of neglected parasitic diseases caused by protozoa of the genus Leishmania. Around 2 million new cases are reported each year and around 12 million people are at risk of being infected. Although various t...
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib [0.03%]
间变性淋巴瘤激酶阳性转移性非小细胞肺癌治疗的最新进展：brigatinib治疗聚焦
Erika Rijavec,Federica Biello,Alice Indini et al.
Erika Rijavec et al.
Rearrangement of anaplastic lymphoma kinase (ALK) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. How...
Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience [0.03%]
Vilolarsen治疗杜氏肌营养不良的药理学特征：日本经验
Rohini Roy Roshmi,Toshifumi Yokota
Rohini Roy Roshmi
Duchenne muscular dystrophy (DMD) is a fatal, X-linked recessive disorder characterized by progressive muscle loss and cardiorespiratory complications. Mutations in the DMD gene that eliminate the production of dystrophin protein are the un...
Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review [0.03%]
硫酸奎宁治疗COVID-19的潜力及其安全特征：综述研究
Irma Rahayu Latarissa,Melisa Intan Barliana,Anna Meiliana et al.
Irma Rahayu Latarissa et al.
The coronavirus disease 2019 (COVID-19) pandemic is currently the largest and most serious health crisis in the world. There is no definitive treatment for COVID-19. Vaccine administration has begun in various countries, but no vaccine is 1...
Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment [0.03%]
尿失禁的药物管理：当前和新兴的治疗方法
Carlo Gandi,Emilio Sacco
Carlo Gandi
Pharmacological management of urinary incontinence (UI) is currently based on antimuscarinic and beta-3-agonist drugs. Botulinum toxin A detrusor injections represent an effective but more invasive alternative. This review covers the latest...
A Case of Thrombocytosis Associated with Enoxaparin Therapy in an Adolescent [0.03%]
青少年使用依诺肝素治疗出现的一例血小板增多症报告
Robert Murray,Joseph T Tobias
Robert Murray
Secondary thrombocytosis, often referred to as a reactive thrombocytosis, is more common than primary thrombocytosis and has many potential etiologies including anemia, infection, inflammation, medications, and post-splenectomy. When consid...
Comparing the Efficacy of a Nurse-Driven and a Physician-Driven Diabetic Ketoacidosis (DKA) Treatment Protocol [0.03%]
比较由护士主导和医生主导的糖尿病酮症酸中毒(DKA)治疗方案的有效性
Takla R Anis,Marybeth Boudreau,Tyson Thornton
Takla R Anis
Background: Standardized DKA treatment could result in better overall safety and efficacy outcomes. The primary objective of this study is to validate the efficacy of an adapted nurse-driven DKA protocol compared to a phy...
Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19 [0.03%]
对于重症但非非重症COVID-19 病人联合抗病毒治疗临床效果优于标准疗法
Prasan Kumar Panda,Budha O Singh,Bikram Moirangthem et al.
Prasan Kumar Panda et al.
Purpose: Definitive antiviral treatment is not available for COVID-19 infection, with the exception of remdesivir, which still evokes many doubts. Various monotherapy or combination therapies with antivirals or other agen...
Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban [0.03%]
抗Xa抑制剂所致出血性瘙痒疹：关于阿哌沙班和利伐沙班之间可能交叉反应的病例报告
Takla R Anis,Whitney Jandreau
Takla R Anis
Direct oral anticoagulants (DOACs) have gained increasing popularity in clinical practice in the past decade. While DOACs have fewer associated adverse events as compared to warfarin, DOAC-induced hypersensitivity is a rare adverse event th...